We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > DRP

News List

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia americanpharmaceuticalreview
April 09, 2021
Acadia Pharmaceuticals Inc. announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment ...
Benzodiazepines With Opioid Agonist Tx May Up Mortality Risk drugs
December 18, 2019
Coprescription of benzodiazepines and opioid agonist treatment (OAT) is associated with an increased risk for drug-related poisoning (DRP) mortality in opioid-dependent individuals ...